Immunocore Holdings plc (ADR)
General ticker "IMCR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Immunocore Holdings plc (ADR) follows the US Stock Market performance with the rate: 16.0%.
Estimated limits based on current volatility of 2.5%: low 27.60$, high 29.02$
Factors to consider:
- Earnings expected soon, date: 2026-05-06 bmo
- Total employees count: 493 (-0.8%) as of 2024
- US accounted for 91.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Market disruptions, Cybersecurity threats, Labor/talent shortage/retention
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [23.56$, 45.27$]
- 2026-12-31 to 2027-12-31 estimated range: [23.38$, 45.21$]
Financial Metrics affecting the IMCR estimates:
- Negative: with PPE of -52.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.44 <= 0.07
- Positive: Interest expense per share per price, % of 0.68 <= 0.73
- Positive: -4.45 < Investing cash flow per share per price, % of -0.68
- Positive: -3.36 < Return on assets ratio (scaled to [-100,100]) of -2.42
Short-term IMCR quotes
Long-term IMCR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £197.39MM | £247.98MM | £297.57MM |
| Operating Expenses | £244.59MM | £304.26MM | £331.31MM |
| Operating Income | £-47.20MM | £-56.28MM | £-33.74MM |
| Non-Operating Income | £-0.98MM | £13.96MM | £19.53MM |
| Interest Expense | £4.08MM | £18.84MM | £12.17MM |
| R&D Expense | £129.42MM | £177.44MM | £204.47MM |
| Income(Loss) | £-48.19MM | £-42.32MM | £-14.21MM |
| Taxes | £-4.43MM | £-1.48MM | £12.21MM |
| Profit(Loss)* | £-53.18MM | £-51.09MM | £-26.42MM |
| Stockholders Equity | £368.84MM | £360.72MM | £381.03MM |
| Inventory | £3.56MM | £5.45MM | £6.74MM |
| Assets | £597.00MM | £1,009.51MM | £1,067.27MM |
| Operating Cash Flow | £2.33MM | £26.06MM | £-7.97MM |
| Capital expenditure | £4.29MM | £5.17MM | £3.23MM |
| Investing Cash Flow | £-4.29MM | £-355.13MM | £-12.16MM |
| Financing Cash Flow | £27.18MM | £343.88MM | £9.20MM |
| Earnings Per Share** | £-1.09 | £-1.02 | £-0.52 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.